{"id":86137,"date":"2026-05-13T10:16:06","date_gmt":"2026-05-13T04:46:06","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=86137"},"modified":"2026-05-13T10:16:07","modified_gmt":"2026-05-13T04:46:07","slug":"goldline-pharmaceutical-ipo-gmp-day-2-may-13-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-gmp-day-2-may-13-2026\/","title":{"rendered":"Goldline Pharmaceutical IPO GMP Day 2 13 May 2026: Grey Market Holds at Rs 17, Subscription Picks Up as Issue Closes Tomorrow"},"content":{"rendered":"

The Goldline Pharmaceutical IPO<\/strong> is on Day 2 of its subscription window on 13 May 2026 with the grey market premium (GMP) holding firm at Rs 16 to Rs 17 per share, implying an expected listing price of approximately Rs 59 to Rs 60 against the upper issue price of Rs 43, a 37 to 40 percent listing premium. Day 1 saw early subscription build-up as retail investors began placing bids, but the bulk of institutional participation from QIBs (allocated 50 percent) is typically concentrated on Day 3. The Goldline Pharmaceutical IPO closes tomorrow, 14 May 2026.<\/p>

The sustained GMP of Rs 16 to Rs 17 across multiple days (from 11 May through today 13 May) is one of the most stable and consistent grey market premiums among all currently open SME IPOs, signalling genuine grey market conviction in the Nagpur-based pharma marketing company. For context, RFBL Flexi Pack, which opened on the same day, has a GMP of Rs 0 versus Goldline Pharma’s Rs 17, making Goldline the standout grey market story in the current SME IPO cycle.<\/p>

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n